Vyvanse 50 MG capsule 100S
Ended Awarded
- Contract number
- SPE2DB25FNWUU
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $6,018
Award facts
- Contract value 100% obligated
- $6,017.62 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $6,017.62 delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Vyvanse 50 mg capsules (100-count units). This is a firm fixed price, non-set-aside contract with a completion date of September 25, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion prime vendor agreement running through December 2026 that serves as the company's comprehensive global pharmaceutical support vehicle for military healthcare programs.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, maintains an extensive portfolio of federal contracts with the Defense Logistics Agency covering a wide range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. The company's demonstrated capability to compete for and execute federal medical procurement requirements, combined with its established relationship through the DLA Troop Support Medical prime vendor contract, positions it as a critical supplier for military and veteran healthcare systems. This specific delivery order for Vyvanse, a controlled-release medication commonly prescribed for attention-deficit/hyperactivity disorder, reflects the ongoing pharmaceutical supply needs of the federal defense medical supply chain.
Quick answers
Who was awarded contract SPE2DB25FNWUU?
SPE2DB25FNWUU was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 24, 2025.
How much is contract SPE2DB25FNWUU worth?
The government has obligated $6,018 on SPE2DB25FNWUU.
Is contract SPE2DB25FNWUU an order under another contract?
Yes. SPE2DB25FNWUU is a delivery order under SPE2DB25D3201, an indefinite delivery contract.
Was contract SPE2DB25FNWUU competed?
The extent of competition for SPE2DB25FNWUU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award